论文部分内容阅读
In this study the aim was to evaluate the intrathecal sICAM-1 production in m ultiple sclerosis (MS) patients during relapse and remission. In addition to thi s,we assessed whether there is a correlation between intrathecal sICAM-1 produc tion and other disease activity markers such as IgG index and gadolinium enhance ment in magnetic resonance imaging (MRI). Twenty four relapsing-remitting MS pa tients were included in the study.Serum and cerebrospinal fluid (CSF) samples we re obtained both during relapse and remission. The soluble form of ICAM(sICAM) w as measured by the ELISA method in serum and CSF. Cranial MRI with triple dose g adolinium injection was performed for each patient both during relapse and remis sion.Serum levels of sICAM-1 (245.23±92.88 ng/ml) were higher during relapse t han those in remission (219.90±110.94 ng/ml),but the difference was not statist ically significant. In relapse periods CSF levels of sICAM-1 (1.304±0.92 ng/ml ) were higher than those in remission (1.06±0.86 ng/ml), but this was not signi ficant. However, during relapse periods patients had significantly higher sICAM -1 index values (1.76±0.60) than those found during remission periods (1.01±0 .44) (p < 0.05). The IgG index values were higher in relapse periods than in rem ission(0.88±0.37 vs. 0.67±0.28) (p < 0.005). On T1 weighted images following t riple dose Gd injection, at least two or more enhancing lesions were present in 22/24 of the patients (91%) in relapse and 4/24 of the patients (19 %) in remi ssion.There was strong correlation both between the sICAM-1 index and Gd enhanc ement (r=0.72 p < 0.05) and sICAM-1 index and IgG index in relapse (r=0.69 p < 0.05). In conclusion, there is association between high sICAM-1 and IgG indices , as well as between high sICAM-1 index and Gd enhancing MRI lesions in relapsi ng MS patients.
In addition to thi s, we assessed whether there is a correlation between intrathecal sICAM-1 produc tion and other disease activity markers such as IgG index and gadolinium enhance ment in magnetic resonance imaging (MRI). Twenty four relapsing-remitting MS pa tients were included in the study. Serum and cerebrospinal fluid (CSF) samples we re obtained both during relapse and remission. The soluble form of ICAM (sICAM) w as measured by the ELISA method in serum and CSF. Cranial MRI with triple dose g adolinium injection was performed for each patient both during relapse and remis sion. Serum levels of sICAM-1 (245.23 ± 92.88 ng / ml) were higher during relapse t han those in remission (219.90 ± 110.94 ng / ml), but the difference was not statistically significant. In relapse CSF CSF of of sICAM-1 (1.304 ± 0.92 ng / ml) were higher than those in remissi on (1.06 ± 0.86 ng / ml), but this was not signi ficant. However, during the relapse periods patients had significantly higher sICAM -1 index values (1.76 ± 0.60) than those found found during remission periods (1.01 ± 0.44) ( The IgG index values were higher in relapse periods than in rem ission (0.88 ± 0.37 vs. 0.67 ± 0.28) (p <0.005). On T1 weighted images of trenple dose Gd injection, at least two or more enhancing lesions were present in 22/24 of the patients (91%) in relapse and 4/24 of the patients (19%) in remi ssion. There was strong correlation both between the sICAM-1 index and Gd enhanc ement (r = 0.72 p <0.05) and sICAM-1 index and IgG index in relapse (r = 0.69 p <0.05). In conclusion, there is association between high sICAM- 1 and IgG indices, as well as between high sICAM-1 index and Gd MRI lesions in relapsi ng MS patients.